Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary,...
Invesco QQQ ETF approved for sale, cross-lists on Hong Kong Stock Exchange
First cross-listing of Invesco QQQ outside of North America; QQQ is the second most traded US ETF Important Information The Trust seeks to track the investment results, before fees and expenses, of the Nasdaq-100 Index® ("Index"). Investors should...
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain...
VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic
SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the...
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by...
Ferrero Group reports Consolidated Financial Statements for the 2023/2024 Financial Year
The Ferrero Group continues its growth trajectory with an 8.9% increase in turnover to EUR18.4 billion. Continued innovation across new products and categories including the launch of Nutella Ice Cream in the same year the brand turns 60 years old....
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market...
Illuccix® Approved in the United Kingdom
MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart...
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects SHANGHAI, Feb. 7, 2025...